- MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF
-
Compounds that inhibit mitogen-activated protein kinases (MAPKs) are disclosed. Some inhibitor compounds specifically target a single MAPK such as MAPK13, while others target multiple MAPKs such as MAPK13 and MAPK12. The compounds can be used therapeutica
- -
-
Page/Page column 76; 78-79
(2019/12/25)
-
- INHIBITORS OF BRUTON'S TYROSINE KINASE
-
Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
- -
-
Paragraph 00835
(2016/01/25)
-
- ANTI-MUCUS DRUGS AND USES THEREFOR
-
Disclosed are methods of identifying, generating and synthesizing compounds that inhibit MAPK13 activity. In various embodiments, compounds, salts thereof and prodrugs thereof of the present teachings can be useful for the treatment of diseases and disord
- -
-
Paragraph 0207; 0208
(2015/07/15)
-
- Process for the preparation of 2,2-bis-chloro-methylalkanecarboxylic acid chlorides
-
A process for the preparation of a 2,2-bis-chloro-methyl-alkanecarboxylic acid of the formula STR1 in which R is hydrogen, alkyl, cycloalkyl or optionally substituted phenyl, which comprises reacting an oxetane-3-carboxylic acid of the formula STR2 or a salt thereof, with an inorganic acid chloride at a temperature between 20° C. and the boiling point of the reaction mixture. The products are known intermediates for fungicides and herbicides.
- -
-
-